Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone
海洛因成瘾者对艾滋病毒治疗的依从性:口服纳曲酮与缓释纳曲酮
基本信息
- 批准号:7756239
- 负责人:
- 金额:$ 47.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-18 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdherenceAgonistAlcohol or Other Drugs useAppointments and SchedulesBehaviorBuprenorphineCD4 Lymphocyte CountCounselingDevelopmentDiseaseDouble-Blind MethodDrug FormulationsDrug Metabolic DetoxicationDrug usageHIVHIV therapyHeroinHeroin DependenceImplantLawsLeadMaintenanceMaintenance TherapyMeasuresMediatingMedicalMethadoneMethodsNaltrexoneObsessive compulsive behaviorOpiate AddictionOpioidOralPatientsPharmaceutical PreparationsPlacebosPlasmaRandomizedRelapseResearchResistanceRisk BehaviorsRussiaScienceSymptomsTabletsTestingTimeTreatment FailureTreatment outcomeUniversitiesUrineViral Load resultWorkaddictionantiretroviral therapycomparative efficacydrug seeking behaviorexperiencehigh risk behaviorimprovedinterestmeetingspreventprimary outcomeprogramspublic health relevanceresponsesecondary outcometherapy adherencetreatment responsetrial comparingviral resistance
项目摘要
DESCRIPTION (provided by applicant): Relapse to opioid addiction in patients with HIV contributes to drug-seeking behavior, non-adherence to antiretroviral therapy (ART), treatment failure, and the development of viral resistance. Successful addiction treatment should do the opposite. Opioid addicted patients receiving ART are often maintained on methadone or buprenorphine, but these medications are subject to regulatory limitations, do not always stop opioid use, are not available in many settings, and not acceptable to all patients. Naltrexone maintenance is another option that could be useful as it blocks opioid effects and prevents relapse if taken as directed. It has been available as a 50 mg tablet that is taken daily and was initially met with enthusiasm by clinicians; however enthusiasm waned when most patients stopped taking it and relapsed. Efforts to develop long-acting formulations that might overcome these problems were realized only very recently, and sustained release formulations are now available and have renewed interest in using it for opioid addiction treatment. These formulations may also facilitate adherence to ART in opioid addicted patients by preventing relapse. Accordingly, this project aims to test whether an implantable formulation that slowly releases naltrexone and blocks opioid effects for 3 months (IN) is more effective than 50 mg/day oral naltrexone (ON) for improving ART adherence and treatment outcome in opioid addicted patients who are beginning their first episode of ART. Russia is an ideal place to study IN since it has an approved product, most HIV patients are heroin addicts, Russian law does not permit agonist treatment, patient interest in naltrexone is high, and the collaborating research team at Pavlov Medical University has extensive experience with IN and ON. To test the hypothesis that IN results in better HIV treatment outcome than ON, we propose a 48-week, randomized, double blind, double- dummy trial comparing IN with ON in 200 recently detoxified heroin addicts beginning their first episode of ART in St. Petersburg. The primary outcomes will be the proportion of patients with a viral load of <400 copies at 24 and 48 weeks. We hypothesize that IN will work better than ON because it will be associated with less relapse and more adherence. PUBLIC HEALTH RELEVANCE: This study will assess the impact of oral naltrexone 50 mg/day vs. a sustained-release naltrexone implant on response to antiretroviral therapy (ART) in opioid addicted patients beginning ART in St. Petersburg, Russia. It will randomize 260 recently detoxified opioid addicts beginning ART to a 48-week course of biweekly drug counseling with oral naltrexone 50 mg/day + placebo naltrexone implant, or placebo tablet + naltrexone implant. The primary outcome will be response to ART as measured by reduction in viral load.
描述(由申请人提供):艾滋病患者阿片类药物成瘾的复发会导致寻求药物的行为,抗逆转录病毒治疗(ART)的不依从性,治疗失败和病毒耐药性的发展。成功的成瘾治疗应该起到相反的作用。接受抗逆转录病毒治疗的阿片类药物成瘾患者通常使用美沙酮或丁丙诺啡维持治疗,但这些药物受到监管限制,并不总能停止阿片类药物的使用,在许多情况下无法获得,也不是所有患者都能接受。纳曲酮维持是另一种有用的选择,因为它可以阻断阿片类药物的作用,并防止复发,如果按照指示服用。它已成为50毫克片剂,每天服用,最初受到临床医生的热烈欢迎;然而,当大多数患者停止服用并复发时,热情就减弱了。开发可能克服这些问题的长效制剂的努力直到最近才实现,现在有了缓释制剂,并重新引起了将其用于阿片类药物成瘾治疗的兴趣。这些配方还可以通过防止复发来促进阿片类药物成瘾患者坚持抗逆转录病毒治疗。因此,本项目旨在测试一种缓慢释放纳曲酮并阻断阿片类药物作用3个月(IN)的可植入制剂是否比50mg /天口服纳曲酮(ON)更有效,以改善开始第一次ART治疗的阿片类药物成瘾患者的ART依从性和治疗结果。俄罗斯是一个理想的地方,因为它有一种批准的产品,大多数艾滋病患者是海洛因成瘾者,俄罗斯法律不允许激动剂治疗,患者对纳曲酮的兴趣很高,巴甫洛夫医科大学的合作研究团队在IN和ON方面有丰富的经验。为了验证IN比ON的HIV治疗效果更好的假设,我们提出了一项为期48周的随机、双盲、双虚拟试验,对圣彼得堡200名最近开始第一次抗逆转录病毒治疗的海洛因成瘾者进行IN和ON的比较。主要结果将是24周和48周时病毒载量<400拷贝的患者比例。我们假设IN会比ON更有效,因为它会减少复发和更多的依从性。公共卫生相关性:本研究将评估在俄罗斯圣彼得堡开始抗逆转录病毒治疗的阿片类药物成瘾患者中,口服纳曲酮50mg /天与缓释纳曲酮植入物对抗逆转录病毒治疗(ART)反应的影响。该研究将随机抽取260名刚开始抗逆转录病毒治疗的阿片类药物成瘾者,进行为期48周的药物咨询,每两周服用口服纳曲酮50mg /天+安慰剂纳曲酮植入物,或安慰剂片+纳曲酮植入物。主要结果将是通过病毒载量的减少来衡量对ART的反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEORGE Edward WOODY其他文献
GEORGE Edward WOODY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEORGE Edward WOODY', 18)}}的其他基金
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone
阿片类药物复发
- 批准号:
8717625 - 财政年份:2012
- 资助金额:
$ 47.24万 - 项目类别:
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone
阿片类药物复发
- 批准号:
8519398 - 财政年份:2012
- 资助金额:
$ 47.24万 - 项目类别:
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone
阿片类药物复发
- 批准号:
9116813 - 财政年份:2012
- 资助金额:
$ 47.24万 - 项目类别:
Opioid Relaps & HIV Risk: 48 vs. 24 Weeks of ER Injectable Naltrexone
阿片类药物复发
- 批准号:
8310620 - 财政年份:2012
- 资助金额:
$ 47.24万 - 项目类别:
Suboxone and Methadone for HIV Risk Reduction in Subutex Injectors
Suboxone 和美沙酮可降低 Subutex 注射器中的 HIV 风险
- 批准号:
7684519 - 财政年份:2009
- 资助金额:
$ 47.24万 - 项目类别:
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone
海洛因成瘾者对艾滋病毒治疗的依从性:口服纳曲酮与缓释纳曲酮
- 批准号:
8143927 - 财政年份:2009
- 资助金额:
$ 47.24万 - 项目类别:
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone
海洛因成瘾者对艾滋病毒治疗的依从性:口服纳曲酮与缓释纳曲酮
- 批准号:
8092869 - 财政年份:2009
- 资助金额:
$ 47.24万 - 项目类别:
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone
海洛因成瘾者对艾滋病毒治疗的依从性:口服纳曲酮与缓释纳曲酮
- 批准号:
8298404 - 财政年份:2009
- 资助金额:
$ 47.24万 - 项目类别:
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone
海洛因成瘾者对艾滋病毒治疗的依从性:口服纳曲酮与缓释纳曲酮
- 批准号:
8288300 - 财政年份:2009
- 资助金额:
$ 47.24万 - 项目类别:
Adherence to HIV Therapy in Heroin Addicts: Oral vs Extended Release Naltrexone
海洛因成瘾者对艾滋病毒治疗的依从性:口服纳曲酮与缓释纳曲酮
- 批准号:
7934539 - 财政年份:2009
- 资助金额:
$ 47.24万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 47.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 47.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 47.24万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 47.24万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 47.24万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 47.24万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 47.24万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 47.24万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 47.24万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 47.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)